# Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)

> **NCT04547140** · PHASE2 · TERMINATED · sponsor: **Grifols Therapeutics LLC** · enrollment: 57 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Liquid Alpha1-Proteinase Inhibitor (Human)
- **DRUG:** Placebo
- **DRUG:** Standard Medical Treatment

## Key facts

- **NCT ID:** NCT04547140
- **Lead sponsor:** Grifols Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-29
- **Primary completion:** 2021-12-13
- **Final completion:** 2022-01-28
- **Target enrollment:** 57 (ACTUAL)
- **Why stopped:** Study Stopped for Futility
- **Last updated:** 2023-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04547140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04547140, "Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT04547140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*